Indications
  • Uncontrolled moderate-to-severe atopic dermatitis for patients ages 6+
  • Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma for patients ages 12+
    Limitation of Use: not for relief of acute bronchospasm or status asthmaticus
  • Inadequately controlled chronic rhinosinusitis with nasal polyposis for patients 18+

The materials for DUPIXENT contained in this virtual exhibition are approved for use only in the United States of America. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the full Prescribing Information and/or the Summary of Product Characteristics (SmPC).

SKIP
SWIPE TO EXPLORE
 
 

Many patients. one dupixent.

DUPIXENT offers a unique mechanism of action that may help control Type 2 inflammation in 3 approved indications1,a

a The mechanism of dupilumab action in asthma has not been established.

EXPLORE THE ONLY BIOLOGIC TO INHIBIT BOTH IL-4 AND IL-13 SIGNALING IN 3 INDICATIONS1

 
 
 
 
 

APPROVED FOR 3 INDICATIONS


EXPLORE ADDITIONAL
INDICATIONS

#1 BIOLOGIC CURRENTLY PRESCRIBED BY ALLERGISTS2

CRSwNP, chronic rhinosinusitis with nasal polyposis.

References: 1. DUPIXENT Prescribing Information. 2. Data on file, Sanofi US. IQVIA Patient Insights; data through September 2020.